Preclinical Testing of New Drugs the CPMP Guidelines as a Model for International Harmonisation
In this time of escalating costs there is a compelling need to minimize the costs in time, money and valuable resources spent on preclinical evaluation of new drugs. International harmonisation of requirements is a major step in this direction.
KeywordsDrug Substance Safety Evaluation Working Party Mutagenicity Test Toxicological Evaluation
Unable to display preview. Download preview PDF.
- Draper M F and Griffin J P (1980) Draft CPMP Guidelines on Mutagenicity Testing. Arch Toxicol (in press)Google Scholar